Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source is commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).